Biosimilars Expected to Take Toll on Amgen

Biosimilar competition to multiple drugs is expected to reduce Amgens sales by nearly US$ 9 Billion during 2013-2020 IMARC Group has recently released a new study suggesting that biosimilars will erode a significant portion of Amgens sales during 2013-2020. According to the report entitled Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020) four products from Amgen - Enbrel (Ethanercept), Epogen (Epoetin Alfa), Neupogen (Filgrastim) and Neulasta (Pegfilgrastim) are expected to face biosimilar competition during 2013-2020. The study that has done a robust analysis on 21 biopharmaceuticals facing biosimilar competition expects the combined sales of Amgens four drugs to decline by US$ 9 Billion during 2011-2020. IMARCs new report entitled Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020) provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.

Key Aspects Analyzed: Evaluating the Current Market Landscape of Biosimilars: Identification of currently marketed biosimilars and their historical performance Identifying the reasons for the slow uptake of currently marketed biosimilars Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilar Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars: Analyzing historical time series data on price, volume and sales erosion in the US & Europe

 Analyzing previous models and assumptions on price and volume erosion caused by biosimilars Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes Evaluating the Market Potential of Biosimilars Across Various Molecules: Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri). Focus of the Analysis for Each Molecule: Historical background and overview Historical brand sales Patent position Competing products Biosimilars in pipeline Brand and biosimilar sales forecast

Evaluating the Sales of Biosimilars across Various Indications: Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency Focus of the Analysis for Each Indication: Historical brand sales Brand and biosimilar sales forecasts Indication wise breakup of molecules Evaluating the Biosimilar Competitive Landscape:

 Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars Identifying biosimilar manufacturers and their pipelines

To obtain the complete report, please contact: Asia: apac@imarcgroup.com Phone: +91-120-425-6531

Europe, Middle East & Africa: ema@imarcgroup.com Phone: +44-702-409-7331

North & South America: america@imarcgroup.com Phone: +1-631-791-1145

To know more please visit: http://www.imarcgroup.com/biosimilarfollow-on-biologicsmarket-report-forecast-a-focus-on-the-us-2011-2020/

Keywords Biosimilar market, biosimilar industry, biogenerics market, us biosimilar market, biosimilar monoclonal antibodies , follow-on biologics market,